RELMADA THERAPEUTICS, INC. SEC Filings

Relmada Therapeutics reported Q2 2026 results and a business update centered on its oncology and CNS pipeline. For the three months ended June 30, 2026, it recorded a net loss of $12,914,185 on $8,393,789 in research and development expenses. Cash, cash equivalents and short‑term investments totaled $217.7 million as of June 30, 2026, and the company raised $159,999,996 from common stock issuance during the first half.

Lead candidate NDV‑01, a sustained‑release intravesical gemcitabine/docetaxel therapy for non‑muscle invasive bladder cancer, showed Phase 2a data in high‑risk patients with high complete response rates. Efficacy‑evaluable participants achieved complete response rates of 95% anytime and 76% at 12 months, with no progression to muscle‑invasive disease or radical cystectomy reported. In a BCG‑unresponsive subgroup, complete response rates were 94% anytime and 80% at 12 months. The company expects to file an NDV‑01 IND by year‑end 2026 and to initiate the Phase 3 RESCUE registrational program after IND clearance. Relmada also plans a year‑end 2026 IND filing for sepranolone, aiming to start a Phase 2 trial in Prader‑Willi syndrome.

Relmada Therapeutics, a clinical-stage biotechnology company, has refocused its pipeline on NDV-01 for non-muscle invasive bladder cancer and sepranolone for Prader–Willi syndrome and related disorders after terminating its esmethadone and psilocybin programs in 2025.

For the quarter ended June 30, 2026, net loss was $12,914,185, contributing to a six‑month net loss of $31,966,141, driven by operating expenses of $15,011,027 in the quarter, including research and development of $8,393,789 and general and administrative expenses of $6,617,238. At June 30, 2026, cash and cash equivalents were $11,334,370 and short‑term investments were $206,396,805, supporting stockholders’ equity of $206,558,323 and an accumulated deficit of $730,233,339.

Equity raises in November 2025 and March 2026 provided net proceeds of approximately $94 million and $150 million, respectively, and management states existing cash and investments should fund operations for at least 12 months. In a Phase 2 study of NDV‑01 in high‑risk non‑muscle invasive bladder cancer, 12‑month complete responses were observed in 19/25 efficacy‑evaluable patients (76%), with no Grade ≥3 treatment‑related adverse events reported.

BlackRock, Inc. reports beneficial ownership of common stock of Relmada Therapeutics Inc.. BlackRock and certain of its subsidiaries and affiliates beneficially own 7,352,913 shares of Relmada common stock, representing 7.0% of the class.

BlackRock has sole voting power over 7,255,400 shares and sole dispositive power over 7,352,913 shares, with no shared voting or dispositive power. The shares are held for various underlying clients and funds; no single underlying person is stated to hold more than five percent of Relmada’s outstanding common shares. The filing is signed by a BlackRock managing director.

Relmada Therapeutics, Inc. appointed Bipin Dalmia, PhD, MBA as chief business officer, as disclosed in a current report dated July 28, 2026. He will lead corporate strategy, commercial planning and business development, reporting directly to chief executive officer Sergio Traversa.

Dalmia brings nearly three decades of biopharmaceutical leadership, including a 14-year tenure at Ferring Pharmaceuticals, where he led the uro-oncology franchise and launch of ADSTILADRIN, described as the first FDA-approved intravesical gene therapy for BCG-unresponsive non-muscle invasive bladder cancer. Relmada describes itself as a clinical-stage biotechnology company developing NDV-01, a novel sustained-release intravesical therapy for NMIBC, and sepranolone for central nervous system conditions; both are characterized as mid-stage programs with potential to address significant unmet needs. The press release detailing the appointment is furnished, not filed, under Regulation FD.

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared voting and dispositive power over 4,567,952 shares of Relmada Therapeutics common stock, representing 4.4% of the class. The cover pages show the position linked to actions around 06/16/2026 and the filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing." The filing includes a Joint Filing Agreement dated June 18, 2026.

Venrock and affiliated entities reported collective beneficial ownership of 6,508,433 shares of Relmada Therapeutics common stock, representing 6.2% of the class. The filing states this percentage is calculated using 104,890,223 shares outstanding as of May 11, 2026. The ownership is held across three primary vehicle buckets: 1,693,738 shares by VHCP III, 169,427 shares by VHCP Co-Investment III, and 4,645,268 shares by VHCP EG. Shared voting and dispositive power of 6,508,433 shares is reported for the group. The Schedule 13G lists the Reporting Persons as a group and identifies management entities and individuals with shared control.

Relmada Therapeutics, Inc. reported that stockholders approved a Charter Amendment increasing authorized common shares from 150,000,000 to 200,000,000. This expands the company’s capacity to issue new stock in the future for financing, compensation, or other corporate purposes.

At the 2026 Annual Meeting, 66,571,711 of 104,888,223 eligible common shares, or about 63.47%, were represented. Stockholders elected two Class II directors, ratified CBIZ CPAs P.C. as independent auditor for 2026, and approved an amendment to the 2021 Equity Incentive Plan, lifting its share pool by 3,000,000 to a total of 18,052,942 shares.

Relmada Therapeutics, Inc. filed an automatic shelf registration on Form S-3 that registers for resale 29,474,569 shares of common stock and shares issuable upon exercise of pre-funded warrants to purchase up to 4,210,527 shares, related to a $160.0 million private placement closed March 9, 2026; the registration was declared effective on April 9, 2026.

The base prospectus also registers a variety of other equity and equity-linked securities (common stock, preferred stock, warrants, subscription rights, depositary shares, purchase contracts and units) for future offerings from time to time. Net proceeds from the private placement are stated to be used for working capital and general corporate purposes, including advancement of R&D for NDV-01 and Sepranolone development programs.

Relmada Therapeutics, Inc. ownership disclosure: Adage Capital Management, L.P. reports beneficial ownership of 4,763,158 shares of Common Stock, representing 4.54% of the class. The percentage is calculated using 104,890,223 shares outstanding as of March 16, 2026. The stake is held directly by Adage Capital Partners, L.P., with reporting by Adage Capital Management, L.P., and tied to the roles of Robert Atchinson and Phillip Gross as managing members of the relevant Adage entities.